

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Health Technology Evaluation**

**Equality impact assessment – Scoping**

**Trastuzumab deruxtecan for treating HER2-positive advanced gastric or gastro-oesophageal junction adenocarcinoma after trastuzumab-based treatment (review of TA879) [ID6680]**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
Yes, stakeholders highlighted that the treatment may have a different impact on older patients with other conditions than on early onset patients.
2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
The committee will consider any equality considerations raised during scoping and the evaluation to ensure that any recommendation is free from discrimination and promotes equality of opportunity.
3. Has any change to the draft scope been agreed to highlight potential equality issues?
N/A
4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

N/A

**Approved by Associate Director (name):** Lorna Dunning

**Date:** 07/04/2026